# Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients

> **NCT00499889** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 42 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Imatinib Mesylate
- **DRUG:** Fludarabine (Fludara)
- **DRUG:** Busulfan
- **DRUG:** Antithymocyte Globulin (ATG)
- **DRUG:** Tacrolimus
- **DRUG:** Methotrexate
- **PROCEDURE:** Donor lymphocyte infusion (DLI)
- **PROCEDURE:** Stem Cell Transplant

## Key facts

- **NCT ID:** NCT00499889
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-02
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Support issue.
- **Last updated:** 2012-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00499889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00499889, "Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00499889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*